New recombinant mutant enzyme prethrombin-2, autocatalytically activated into active thrombin.

CIC biomaGUNE is a research center at the interface between the chemical, biological and physical sciences and with a main emphasis on the study of the interaction of biofunctional nanostructures with biological systems, its applications and properties at the molecular and nanometer scale.

INNOVATION IN HEMOSTASIS

  • The recombinant mutant enzyme prethrombin-2 contains a cleavage site for thrombin and is autocatalytically activated into active thrombin.
  • The present invention provides recombinant mutant human and murine prethrombin-2 with autocatalytic activation activity. The product resulting from the activation of this proenzyme with thrombin, catalyses the activation of the proenzyme in an autocatalytic activation process. The result is a rapidly spreading cascade of prethrombin conversion that results in an immediate effect associated to the thrombin activity.
  • In the absence of thrombin or other activating agent, the proenzyme is completely stable.

ADDITIONAL INFORMATION

  • Autocatalytic prethrombin-2 is highly stable.
  • Compatible with large-scale thrombin production using bacterial expression systems.
  • Example applications include its use as hemostatic drug; thrombin detection; prothrombin detection in human plasma and its use as biochemical assays by signal amplification cascade.

PATENTS

International patent application PCT No. WO 2013/064542

National phases of the international application are currently granted in:

National phase in Canada is pending.

All patents have been prosecuted by the firm Manuel Illescas y Asociados, S.L.U.

Recombinant mutant enzyme prethrombin-2, uses and kits for detecting thrombin/prothrombin and methods for producing thrombin are protected.